Compare · CELZ vs MCO
CELZ vs MCO
Side-by-side comparison of Creative Medical Technology Holdings Inc. (CELZ) and Moody's Corporation (MCO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELZ and MCO operate in Finance: Consumer Services (Finance), so they compete in similar markets.
- MCO is the larger of the two at $81.18B, about 9547.8x CELZ ($8.5M).
- Over the past year, CELZ is up 13.1% and MCO is up 3.7% - CELZ leads by 9.3 points.
- MCO has been more active in the news (9 items in the past 4 weeks vs 1 for CELZ).
- MCO has more recent analyst coverage (25 ratings vs 1 for CELZ).
- Company
- Creative Medical Technology Holdings Inc.
- Moody's Corporation
- Price
- $2.25-2.60%
- $456.11+0.81%
- Market cap
- $8.5M
- $81.18B
- 1M return
- +19.68%
- +6.54%
- 1Y return
- +13.07%
- +3.72%
- Industry
- Finance: Consumer Services
- Finance: Consumer Services
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 1
- 9
- Recent ratings
- 1
- 25
Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem for the treatment of erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine for the treatment of chronic lower back pain; Amniostem for the treatment of strokes, radiation, toxicity, and glioma; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. was incorporated in 1998 and is based in Phoenix, Arizona.
Moody's Corporation
Moody's Corporation operates as an integrated risk assessment firm worldwide. It operates in two segments, Moody's Investors Service and Moody's Analytics. The Moody's Investors Service segment publishes credit ratings and provides assessment services on various debt obligations, programs and facilities, and entities that issue such obligations, such as various corporate, financial institution, and governmental obligations; and structured finance securities. This segment provides ratings in approximately 140 countries. Its ratings are disseminated through press releases to the public through electronic media, including the internet and real-time information systems used by securities traders and investors. This segment has rated approximately 5,000 non-financial corporates; 3,600 financial institutions; 16,000 public finance issuers; 145 sovereigns; 47 supranational institutions; 459 sub-sovereigns; and 1,000 infrastructure and project finance issuers, as well as 9,100 structured finance deals. The Moody's Analytics segment develops a range of products and services that support the risk management activities of institutional participants in financial markets; and offers subscription based research, data, and analytical products comprising credit ratings, credit research, quantitative credit scores and other analytical tools, economic research and forecasts, business intelligence and company information products, commercial real estate data and analytical tools, and on-line and classroom-based training services, as well as credentialing and certification services. It also offers software solutions, as well as related risk management services; and offshore analytical and research services with learning solutions and certification programs. The company was formerly known as Dun and Bradstreet Company and changed its name to Moody's Corporation in September 2000. Moody's Corporation was founded in 1900 and is headquartered in New York, New York.
Latest CELZ
- Amendment: SEC Form 10-K/A filed by Creative Medical Technology Holdings Inc.
- SEC Form 10-K filed by Creative Medical Technology Holdings Inc.
- Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline
- Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain
- Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point
- SEC Form 424B3 filed by Creative Medical Technology Holdings Inc.
- SEC Form EFFECT filed by Creative Medical Technology Holdings Inc.
Latest MCO
- SEC Form 10-Q filed by Moody's Corporation
- Moody's Corporation Achieved Record Results For First Quarter 2026
- Moody's Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Moody's Advances Decision-Grade Credit Intelligence Across Enterprise AI Workflows, Powered by Microsoft 365 Copilot
- Moody's Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Moody's Agentic Solutions Now Available in AWS Marketplace
- Moody's Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Moody's Corporation Names Christina Kosmowski as CEO of Moody's Analytics
- Moody's Brings Credit and Compliance Workflows Directly into Anthropic's Claude
- SEC Form 4 filed by Minaya Jose